In childhood, thrombocytopenia caused by transient antibody-mediated thrombocyte destruction is most frequently diagnosed as immune thrombocytopenic purpura (ITP). We report the case of a girl with ITP associated with autoimmune thyroiditis. Case presentation: A 11-year-old female patient with Hashimoto's thyroiditis presented with clinical signs of petechiae and ecchymoses on the extremities. Laboratory tests showed remarkable thrombocytopenia with a platelet count of 44,500/μL, hence she was referred to a hematologic consultation. The peripheral blood smear showed normal size platelets in very low range. The bone marrow examination exposed hyperplasia of the megakaryocyte series with outwardly morphologic abnormalities. The patient was diagnosed with ITP, and her first-line treatment was pulsed steroid and immunoglobulin therapy. The thrombocytopenia was refractory to these first-line medications. After 6 months of corticotherapy and a period of severe menorrhagia, azathioprine immunosupression was initiated as a second-line treatment. Her platelet count rapidly increased, and the evolution was good, without bleeding complications. Conclusion: In case of a medical history of autoimmune diseases and treatment-resistant ITP, attention must be focused on detecting coexisting autoimmune diseases and adjusting the treatment in accordance with the chronic evolution of the disease.
InTROduCTIOn
Immune thrombocytopenic purpura (ITP) is a non-malignant hematologic disorder mediated by autoantibodies, characterized by destruction and impaired production of platelets. 1 Primary ITP is rare, with an incidence of 3-5 cases/100,000 children/year, and the secondary form of ITP is related to coexisting conditions such as immunodeficiency, rheumatic disorders, drugs, or infectious diseases. 1 The characteristic clinical indicators of ITP include easy bruising of the skin, or mucocutaneous lesions such as petechiae and ecchymoses, epistaxis, and gingival bleeding. 2 
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The prognosis of ITP is primarily determined by the risk of spontaneous hemorrhage and the low platelet count. 1 The classification of ITP describes three classes: newly diagnosed ITP (<3 months), persistent ITP (3-12 months), and chronic ITP (cITP), lasting for more than 12 months and usually associated with significant hemorrhagic or thrombotic complications. The standard first-line therapy for ITP consist in corticosteroids and intravenous immunoglobulins (IVIG). 2, 3 Childhood ITP is a heterogeneous disease, which can coexist with several autoimmune diseases, 3 especially in the chronic forms associated with systemic lupus erythematosus (SLE), autoimmune thyroiditis, and hemolytic anemia. 4, 5 The combination of immune thrombocytopenia with thyroid autoimmune diseases is an infrequent but well-known condition. 6 The most common organ-specific autoimmune diseases that affect the endocrine glands in children are Hashimoto's thyroiditis and type 1 diabetes mellitus. [7] [8] [9] ITP treatment protocols are used to increase platelet count to a safe point, to prevent severe bleeding complications, and to reduce the mortality index. Patients with platelet count <30.000/μL are at a high risk of bleeding complications. 10 Current treatment protocols include glucocorticoids and immunoglobulins as first-line therapy and immunomodulatory agents or splenectomy as second-line treatment. About 80% of children show a very good response to single-medication treatment or the association of firstline medications, which includes periodic complete blood count, corticosteroid medication, and IVIG. However, there are patients who fail to respond to these therapies. 11, 12 For these patients, second-line treatments may be indicated such as: anti-CD 20 (rituximab) or immune suppression to reduce the production of antiplatelet antibodies. Splenectomy can also be recommended as a second-line option for ITP patients; however, this is associated with a high risk for relapse or for treatment failure. 11, 12 Several new treatment protocols have been suggested, such as eltrombopag (an oral nonpeptide thrombopoietin receptor agonist) and romiplostim (subcutaneously administered peptide mimetic thrombopoietin receptor agonist), which were found effective in children with chronic forms. 10, 13 Regarding the adverse effects and safety of eltrombopag and romiplostim, these options seem to be superior to other first-line or second-line therapies.
Here we present the case of an 11-year-old adolescent with chronic ITP associated with autoimmune thyroiditis, an uncommon combination in the autoimmune disease spectrum. The patient and the institution agreed to the publication of the patient's data, and all the procedures and manuscript preparation were done according to the ethical principles stated in the Declaration of Helsinki.
CASE REPORT
An 11-year-old girl was admitted to the Hematology Department with a 3-day history of widespread cutaneous signs appearing without significant trauma, such as petechiae on the face, abdomen and extremities, and ecchymoses predominantly on the lower extremities. The patient was referred to our department by the general practitioner. The patient was the only child of non-consanguineous parents, and the family history did not report any hematologic/immunologic conditions or autoimmune disease.
At the age of 10, during a general screening occurring in the school, the patient was diagnosed with Hashimoto's thyroiditis, which was treated with per oral administration of levothyroxine (Euthyrox) 50 mg for one year. Recent medical history showed frequent infections, refractory tonsillitis, and repeated antibiotic treatments in the past year.
The general status of the patient was acceptable, and physical examination revealed an enlarged spleen. Laboratory findings were suggestive for a hematologic disorder: white blood cell count 3,790/μL, neutrophil count 1,500/μL, thrombocytes 44,500/μL, hemoglobin (Hb) 13.86 g/dL, and reticulocytes 9‰. The peripheral blood smear displayed modified morphology of the platelet cells (Table 1) . Lactate dehydrogenase was within the normal range (201 IU/L), and other laboratory tests were without pathological modifications.
Serology tests for HIV, hepatitis B, and hepatitis C, as well as anti-nuclear antibodies and rheumatoid factor levels were negative. In order to differentiate between ITP purpura or an eventual hematologic malignancy, additional investigations were performed including bone marrow examination, which revealed an increased number of • The bone marrow shows an increase number of megakaryocytic, especially immature forms -suggestive aspect for ITP young forms of megakaryocytes and rare micromegakaryocytes, as well as mature forms, an aspect highly suggestive for ITP. Figure 1 illustrates the treatment protocol used in the follow-up period. Steroid treatment has been introduced, leading to a fast increase in platelet count on the following day (72,000/μL), which was augmented 3 days later (167,500/μL).
The adolescent was diagnosed with ITP and Hashimoto's thyroiditis, and was recommended to continue at home the steroid treatment with Medrol 3 × 16 mg/day for one week, and to taper the dosage for 4 weeks. Hashimoto's thyroiditis with hypothyroidism was also re-evaluated and treated with continuous levothyroxine (Euthyrox 75 mg, 1 tablet daily).
After one month, the additional tapering of Medrol to a dose of 8 mg/day led to a rapid decrease of platelet count to an extremely low level (22,530/μL), and after a dose of intravenous immunoglobulin (5 g i.v.), the previous dose of Medrol had to be reinstated. After another 3 months, steroid treatment was stopped, which led to a second relapse in 20 days (PLT 12,000/μL), with severe menorrhagia. This time, the acute treatment was hormonal suppression.
The patient's ITP was resistant to treatment with IVIG and oral corticotherapy. We administered an immunoglobulin dose, and after further immunologic investigations (RF, ANA, IgG anti-Helycobacter pylori antibodies, IgM antiphospholipid antibodies, Coombs test levels were negative), we decided to start second-line therapy with immunosuppressive medication consisting in azathioprine in a dose of 2 mg/kg/day (Imuran 2 × 50 mg/day). After 2 years of Imuran in full dose and 1 year in half dose, and after reaching a normal platelet count in these 3 years, we decided to stop the immunosupression, and the patient was finally discharged with an oral treatment of Prednison 5 mg/day.
In light of this interesting clinical picture and the particular response to treatment, we established the diagnosis of chronic ITP associated with another autoimmune disease, Hashimoto's thyroiditis.
dISCuSSIOn
The aim of this case report was to reveal the possible presence of polyautoimmunity in autoimmune pathologies and the role of autoimmune thyroiditis as a prognostic factor for chronic ITP. Autoimmune thyroiditis is very FIGURE 1. Platelet count during the treatment and follow-up period frequent in children and young adults. 8 In our case, the clinical picture was consistent with hypothyroidism on hormonal treatment for one year. In both adults and children, Hashimoto's thyroiditis is the most common cause of thyroid disorders; 14 however, the association between ITP and other autoimmune diseases has been described in a small number of studies. 15 Acute thrombocytopenia can result from a transient malfunction of the immune system during an acute infection, but chronic forms are usually the consequence of an extended perturbation of the immune system and can indicate the presence of another autoimmune disease. 15, 16 Childhood ITP presents mostly as an acute form occurring in the 2-10 year age group, with a peak incidence at the age of 2-4 years. The disease occurs mostly after a viral infection or immunization, and recovery can be observed within six months. Usually, ITP in adolescents and adults has no conceivable precipitating factor, displays a chronic course, and appears associated with other autoimmune diseases. 17 Literature data proves that autoimmune thyroiditis is one of the most regularly diagnosed immune disorders in ITP patients. 17 Our adolescent had a primary diagnosis of autoimmune thyroiditis and ITP as a second pathology after one year. The symptomatology of ITP is extremely variable and ranges from the common presentation of a patient with mild bruising and mucosal bleeding (oral or gastrointestinal tract bleeding, menorrhagia) to severe bleeding. 17 Overall, symptomatic bleeding is rare unless the ITP is severe with extremely low platelet count (<30,000/μL). In this case, the cutaneous bleeding was present with a 42,000/μL platelet count, and severe menorrhagia with 12,000/μL. Although there is a poor correlation between the degree of thrombocytopenia and bleeding, severe cutaneous bleeding, prolonged epistaxis, gingival bleeding, hematuria, or menorrhagia may appear at platelet counts below 10,000/μL. Our female adolescent with ITP had medium bleeding events and one severe menorrhagia event. The patient initially responded favorably to treatment with corticosteroids (Medrol), but the treatment had side effects, and she relapsed after two pulses of Medrol (PLT 41,000/μL). The side effects of steroid treatment were gastritis, weight gain, striae, moon face.
This case demonstrates the chronic development of ITP associated with other autoimmune pathologies, in this case with Hashimoto's thyroiditis. For patients with no immediate risk of bleeding and no effective long-term treatments available, the literature recommends an observeand-wait approach as the only option. 18 In our case, the severe bleeding event occurred during steroid treatment and immunoglobulin administration. Due to menorrhagia after the acute treatment, we decided to introduce the immunosuppressive treatment with azathioprine (Imuran). Although most second-line therapies succeed to achieve an adequate response, they are associated with substantial side effects, mainly immunosuppression. 15, 19 We believe that treatment with eltrombopag should be considered for this population in order to return to their normal desired activities without restriction and eliminate the necessity for treatments with severe side effects. At that time, we did not have the possibility to use the thrombopoietin receptor agonist.
Notably, after 2 years of oral immunosuppressive treatment, the patient's platelet count was within normal range, the treatment was stopped, and currently we are in a waitand-watch period.
